The enzymes that determine protein O-GlcNAcylation, O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), act on key transcriptional and epigenetic regulators, and both are abundantly expressed in the brain. However, little is known about how alterations in O-GlcNAc cycling affect human embryonic stem cell (hESC) neural differentiation. Here, we studied the effects of perturbing O-GlcNAcylation during neural induction of hESCs using the metabolic inhibitor of OGT, peracetylated 5-thio-N-acetylglucosamine (Ac 4 -5SGlcNAc). Treatment of hESCs with Ac 4 -5SGlcNAc during induction limited protein OGlcNAcylation and also caused a dramatic decrease in global levels of UDP-GlcNAc. Concomitantly, a subpopulation of neural progenitor cells (NPCs) acquired an immature neuronal morphology and expressed early neuronal markers such as β-III tubulin (TUJ1) and microtubule associated protein 2 (MAP2), phenotypes that took longer to manifest in the absence of OGT inhibition. These data suggest that chemical inhibition of OGT and perturbation of protein O-GlcNAcylation accelerate the differentiation of hESCs along the neuronal lineage, thus providing further insight into the dynamic molecular mechanisms involved in neuronal development. O -GlcNAcylation of serine or threonine residues is a widespread modification of nuclear, cytoplasmic, and mitochondrial proteins that is dynamic and reversible on the time scale of hours or even seconds.
O -GlcNAcylation of serine or threonine residues is a widespread modification of nuclear, cytoplasmic, and mitochondrial proteins that is dynamic and reversible on the time scale of hours or even seconds. 1−4 Unlike phosphorylation, which is regulated by hundreds of kinases and phosphatases, only one O-GlcNAc transferase (OGT) installs the GlcNAc residue, and a single O-GlcNAcase (OGA) removes it. UDP-GlcNAc, the nucleotide sugar donor for OGT, is produced via the hexosamine biosynthetic pathway (HBP), and its levels are highly responsive to intracellular concentrations of glucose, amino acids, and lipids. 5 This sensitivity allows O-GlcNAcylation to respond to changes in nutrient availability and the cell's metabolic state. 6 Moreover, maintaining a proper balance of O-GlcNAc in the cell is important, as the dysregulation of O-GlcNAcylation underlies several disease states. 7 A number of studies point to a role for O-GlcNAcylation in stem cell maintenance and differentiation. The complete absence of OGT is lethal to mouse ESCs and embryos, 8 and experiments with conditional alleles reveal that OGT is required in a tissue-specific manner at later stages of development. 9 O-GlcNAcylation has been shown to both enhance and suppress activity of proteins important for embryonic stem cell (ESC) pluripotency and differentiation. 10−15 Jang and colleagues reported that a loss of OGT reduced proliferation and self-renewal of ESCs. 11 Conversely, high O-GlcNAcylation decreased differentiation of these cells. The study also showed that O-GlcNAcylation of pluripotency factors OCT4 and SOX2 was necessary for maintaining ESC pluripotency. In contrast, a recent study by Myers et al. showed that O-GlcNAcylation of SOX2 at a specific serine residue inhibited stem cell pluripotency and maintenance, suggesting a new mechanism by which O-GlcNAc regulates SOX2 in response to developmental cues. 15 O-GlcNAcylation seems to be particularly important in brain development. Many proteins important for neuronal cell signaling, synaptic plasticity, learning, and memory are OGlcNAc-modified. 4,16−19 Indeed, studies of brain-specific OGT knockout mice point to a role for O-GlcNAc in neuronal function and neurodegeneration. 9,20−22 Liu et al. reported higher levels of O-GlcNAc, OGT, and OGA in neurons compared to non-neuronal cells in the rat brain. 23 Maintaining high levels of O-GlcNAcylation prevents ectodermal differentiation of mouse ESCs, 13 impairs axonal branching, 24 and inhibits proteasome function. 25 A recent study using human embryonic stem cells (hESCs) found that excess O-GlcNAc decreased the expression of neural markers PAX6 and SOX1. 26 However, the authors did not examine the effect of decreasing O-GlcNAc during hESC differentiation.
Here, we characterize O-GlcNAc cycling during neural induction of hESCs and the effect of chemical inhibition of OGT on the differentiation process. We found that O-GlcNAc levels oscillate during neural differentiation both with and without OGT inhibition by Ac 4 -5SGlcNAc. Upon treatment with the inhibitor, we also observed that neural progenitor cells (NPCs) gained morphology reminiscent of immature neurons, acquiring the neuronal markers β-III tubulin (TUJ1) and microtubule-associated protein 2 (MAP2) on a faster time scale than without OGT inhibition. Gene expression analysis revealed that genes involved in neuronal differentiation and forebrain development were significantly upregulated in OGTinhibited cells. These findings improve our mechanistic understanding of neural differentiation and may provide a faster route to generate neurons from hESCs.
■ RESULTS AND DISCUSSION
Global O-GlcNAcylation Oscillates As hESCs Differentiate to NPCs. hESCs were differentiated into NPCs using the dual SMAD-inhibition protocol ( Figure 1A) . 27 This protocol relies on the synergistic action of SB431542 (SB), which inhibits the Lefty/Activin/TGFβ pathways, and LDN-193189 (LDN) or Noggin, inhibitors of bone morphogenetic protein (BMP). During NPC formation, expression of the pluripotency marker OCT4 was undetectable by Western blot after day 2 of neural induction, while the emergence of transcription factor and neuroectodermal marker PAX6 was clearly observed by Western blot 4 days post induction ( Figure  1B ). This indicated a successful differentiation of the hESC line H1 to NPCs over 11 days, as reported previously. 27 We then analyzed global O-GlcNAcylation at every day of neural differentiation by Western blot with an O-GlcNAc-specific antibody (RL2). Global O-GlcNAc levels oscillated during hESC neural induction, dramatically decreasing after day 9 of Quantitation of UDP-GlcNAc levels on each day of neural differentiation by high performance anion exchange chromatography (HPAEC; n = 4; mean ± SEM; *P < 0.05, **P < 0.01). H1 refers to undifferentiated hESCs. (E) Western blot analysis of HBP enzymes during each day of neural differentiation. H1 refers to undifferentiated hESCs.
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Articles induction. The expression of both OGT and OGA also decreased toward the end of the neural induction protocol ( Figure 1B) , as has been seen in studies of O-GlcNAcylation in rat brain and mouse embryonic neural precursor cells. 23, 28 However, OGT and OGA protein expression did not oscillate similarly to O-GlcNAc levels. Together, these data suggest that a decrease in O-GlcNAcylation may be important for neural induction of hESCs and that the oscillation in the levels of OGlcNAc is not due to changes in OGT and OGA abundance.
Protein O-GlcNAcylation is influenced by glucose flux through the HBP, which produces UDP-GlcNAc ( Figure  1C ). Levels of UDP-GlcNAc are positively correlated to cellular protein O-GlcNAcylation. 29 To determine whether the availability of UDP-GlcNAc might be correlated with the observed difference in global O-GlcNAc levels between the hESCs and NPCs, we measured the levels of UDP-GlcNAc at every day of differentiation. Analysis of extracted UDP-GlcNAc using high performance anion exchange chromatography (HPAEC) revealed a similar fluctuation in the levels of the nucleotide sugar donor to global protein-associated O-GlcNAc in the early stages of neural induction ( Figure 1D ). Given that cellular differentiation is generally associated with proliferation and increased metabolic requirement, 30 it is possible that the changes in UDP-GlcNAc concentration reflect a difference in glucose flux through the HBP. This result might suggest that protein O-GlcNAcylation is being modulated in part by the cellular concentration of UDP-GlcNAc. Notably, though, UDPGlcNAc levels toward the end of neural differentiation did not parallel the dramatic decrease observed in global protein OGlcNAcylation.
To determine if changes in the expression of the enzymes in the HBP were responsible for the observed changes in UDPGlcNAc levels during neural induction, we analyzed the protein levels of every enzyme in the HBP by Western blotting. As shown in Figure 1E , the protein levels of HBP enzymes remained constant during the beginning of the neural induction, except for the enzymes UDP-N-acetylglucosamine pyrophosphorylase 1 (UAP1) and N-acetylglucosamine kinase (NAGK), whose expression seems to drop off as early as day 3 and 5, respectively. Interestingly, as we observed for OGT and OGA, the abundance of most enzymes in the HBP decreased toward the end of differentiation, including the enzymes glutamine fructose-6-phosphate amidotransferase (GFAT1) and phosphoglucomutase 3 (PGM3). Although GFAT1 is the rate-limiting enzyme of HBP, its decrease in expression does not correlate with the increase in UDP-GlcNAc levels on day 11. It has been shown that UDP-GlcNAc levels are also influenced by the expression of the enzyme glucosaminephosphate N-acetyltransferase 1 (GNPNAT1), whose expression is mostly constant during the neural induction. 31 Similarly, the expression of the enzyme UDP-galactose-4-epimerase (GALE) did not change during neural induction. The lack of correlation between HBP enzyme expression and O-GlcNAc levels could be due to consumption of UDP-GlcNAc in other glycosylation pathways.
Changes in the expression of glucose transporters, such as GLUT1 and GLUT4, have been shown to influence UDPGlcNAc levels in mice. 32 While we did not examine these proteins directly, the transcript levels of the transporters GLUT1 (SLC2A1) and GLUT3 (SLC2A3) increased as cells differentiated toward NPCs, whereas the transcript levels of GLUT4 (SLC2A4) decreased during neural induction (vide inf ra and Supporting Information Figure 1 ). These results correspond to an increase in glucose uptake 32 and possibly account for the increase in UDP-GlcNAc levels at later days of differentiation. Furthermore, both GLUT1 and GLUT3 have been shown to be important in brain metabolism and development. 33 Treatment with the OGT Inhibitor Ac 4 -5SGlcNAc Lowers Global O-GlcNAc Levels in Differentiating hESCs. To determine whether global O-GlcNAcylation influences the process of neuronal differentiation, we used the small molecule peracetylated 5-thio-N-acetylglucosamine (Ac 4 -5SGlcNAc) recently shown by Gloster et al. to disrupt the catalytic activity of OGT.
34 Ac 4 -5SGlcNAc is converted within cells to UDP-5SGlcNAc, a nucleotide sugar analogue of UDPGlcNAc that competes with the native substrate and inhibits protein O-GlcNAcylation by OGT. As well, Ac 4 -5SGlcNAc reduces the cellular pool of native UDP-GlcNAc, another mode by which it may suppress protein O-GlcNAcylation.
We first tested various inhibitor doses to identify concentrations of Ac 4 -5SGlcNAc that decrease global OGlcNAcylation, as determined by Western blot with the anti-O-GlcNAc antibody. As shown in Supporting Information Figure 2A , treatment with 50 μM Ac 4 -5SGlcNAc for 24 h abrogated the majority of detectable protein O-GlcNAcylation. We also observed that treatment with Ac 4 -5SGlcNAc for 5 days led to a time-dependent decrease in O-GlcNAc for up to 3 days, after which time O-GlcNAc levels started to increase (Supporting Information Figure 2B ). We also observed a decrease in OGA protein expression during the 5-day period. This may reflect a feedback mechanism in which reduction in OGT activity and protein O-GlcNAcylation leads to downregulation of OGA expression. 34, 35 OGT inhibition by Ac 4 -5SGlcNAc did not affect hESC pluripotency, as measured by OCT4 expression (Supporting Information Figure 2B ). Importantly, treatment of cells with the OGT inhibitor did not cause apparent changes in cell morphology and proliferation (Supporting Information Figure 2C ).
We next analyzed global O-GlcNAcylation levels after treating neural-induced hESCs with 50 μM Ac 4 -5SGlcNAc ( Figure 2A ). Overall, O-GlcNAcylation levels were lower in inhibitor-treated cells, but the oscillation pattern characteristic of the neural differentiation process was maintained ( Figure  2B ). As above, perturbations in O-GlcNAc cycling induced a compensatory decrease in OGA and an increase in OGT protein levels. The expressions of OCT4 and PAX6 were not affected by the OGT inhibitor ( Figure 2B ). Furthermore, we observed lower UDP-GlcNAc levels when differentiating cells in the presence of Ac 4 -5SGlcNAc, as previously reported by Gloster et al. (Figure 2C ). 34 These results confirm that Ac 4 -5SGlcNAc is metabolized by the cells and inhibits protein OGlcNAcylation. Also, the oscillatory pattern in both O-GlcNAc and UDP-GlcNAc levels during neural induction, even after OGT inhibition, indicates a possible regulatory mechanism utilized by hESCs to properly differentiate into NPCs.
OGT Inhibition Promotes Neural Differentiation of hESCs. We next asked whether treatment of hESCs with Ac 4 -5SGlcNAc during neural induction caused perturbations in the differentiation process. Treatment of hESCs with 50 μM Ac 4 -5SGlcNAc for 48 h prior to initiating neural induction with SMAD inhibitors accelerated expression of the neuronal marker TUJ1 compared to noninhibited cells (Supporting Information Figure 3A ). Thus, all further neural inductions were performed in the presence of OGT inhibitor from day −2 to 11, and LDN and SB from day 0 to 5. Compared to cells treated with DMSO,
Articles hESCs differentiated in the presence of Ac 4 -5SGlcNAc prematurely expressed TUJ1 as early as day 8, and immunofluorescence analysis confirmed that they displayed greater extension of neurites ( Figure 3A , Supporting Information Figure 5A ). Similarly, we observed colabeling of neuronal markers TUJ1 and MAP2 by day 11 of induction in the presence of Ac 4 -5SGlcNAc in multiple hESC lines: H1, H9, and H7 ( Figure 3B and Supporting Information Figure 3B ). This underscores the reproducibility of these effects of OGT inhibitor treatment during neural differentiation of hESCs. Similar results were obtained when cells were treated with a lower concentration of Ac 4 -5SGlcNAc (10 μM) during neural induction (Supporting Information Figure 3C ).
We also analyzed TUJ1 and MAP2 expression by flow cytometry analysis. In line with the microscopy results, we observed a rapid increase in the coexpression of these markers as early as day 6 of neural differentiation in the presence of Ac 4 -5SGlcNAc, with a 10-fold difference in expression between Ac 4 -5SGlcNAc-treated and DMSO-treated cells ( Figure 3C ). Coexpression of TUJ1 and MAP2 in Ac 4 -5SGlcNAc-treated cells continued to increase until day 11, at which point 3% of Ac 4 -5SGlcNAc-treated cells were coexpressing both neuronal markers, compared to 1% of DMSO-treated cells. Notably, MAP2 staining has been shown to follow TUJ1 labeling and is found in brain regions where the cell bodies of more mature neurons are located. 36 TUJ1 was found to be O-GlcNAc modified in retinal pigment epithelial cells and mouse brain. 37, 38 In addition, previous studies have shown that OGlcNAcylation of tubulin proteins inhibits their polymerization and negatively regulates microtubule formation. 39 These findings suggest that a decrease in O-GlcNAcylation of TUJ1 proteins might be involved in increased microtubule formation and neuronal growth. Figure 1D ) or Ac 4 -5SGlcNAc (blue line, concentration at 50 μM; n = 3−4; mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001). hESCs shows a higher percent of coexpression of TUJ1 and MAP2 in cells treated with Ac 4 -5SGlcNAc than cells treated with DMSO (day 4, 6, 7, n = 2; day 8, 11, n = 6; mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001).
Articles Additionally, as shown above, we did not detect a difference in OCT4, SOX2, or PAX6 expression when cells were treated with Ac 4 -5SGlcNAc ( Figures 2B, 3A and Supporting Information Figure 6 ). These results suggest that the accelerated neuronal induction produced by OGT inhibition is not due to a premature exit from the pluripotent state and entrance into the neural progenitor state controlled by the abundance of OCT4, SOX2, and PAX6. SOX2 is involved in hESC pluripotency and differentiation, 40 and it is known to be O-GlcNAcylated. 10, 11, 15 Thus, it would be interesting to investigate whether its O-GlcNAcylation state and its interaction with other transcriptional regulatory proteins is altered due to hESC treatment with Ac 4 -5SGlcNAc, 15 and consequently, whether these alterations are involved in the mechanism that accelerates hESC neural induction.
A complicating feature of Ac 4 -5SGlcNAc is that it can affect glycosylation pathways beyond O-GlcNAcylation, possibly causing pleiotropic effects that convolute biological studies. Indeed, Walker and co-workers found Ac 4 -5SGlcNAc to affect glycosylation of proteins that populate the cell surface, presumably due to inhibition of other glycosyltransferases or depletion of nucleotide sugars. 35 As well, Gloster et al. reported that cells convert Ac 4 -5SGlcNAc to UDP-5SGalNAc, which in turn decreased the endogenous UDP-GalNAc pool. 34 As UDPGalNAc is the sugar donor for polypeptide GalNAc transferases that initiate mucin-type O-glycosylation, this finding suggests that Ac 4 -5SGlcNAc treatment can affect this sector of the glycome as well.
To determine whether cell-surface glycosylation patterns of hESCs are grossly perturbed by Ac 4 -5SGlcNAc, we performed staining experiments with the fluorescent lectins Canavalia ensiformis agglutinin (ConA), Lens Culiniaris Agglutinin (LCA), Artocarpus integrifolia agglutinin (AIL or Jacalin), and Arachis hypogaea agglutinin (PNA). Jacalin and PNA are lectins that bind galactose/N-acetylgalactosamine residues in mucin Oglycans, whereas LCA and ConA are lectins that bind the highmannose core region of N-glycans. hESCs treated with 50 μM Ac 4 -5SGlcNAc or DMSO vehicle for 4 days of neural induction stained similarly with Jacalin and LCA, as determined by flow cytometry (Supporting Information Figure 4 ). In contrast, we observed significant differences between inhibitor-and vehicletreated cells when we stained with PNA and ConA, specifically on day −2 and day 0. However, we did not observe differences in cell surface staining by any of the lectins on day 2 of neural induction. Thus, while Ac 4 -5SGlcNAc may have pleiotropic effects on hESC glycosylation beyond protein O-GlcNAcylation, these appear minimal once neural induction is underway.
Pursuant to these observations, we sought to determine whether intentional modifications to cell surface glycosylation reproduced the same neuronal phenotype seen under treatment with Ac 4 -5SGlcNAc. We differentiated hESCs in the presence of the O-glycosylation inhibitor benzyl-α-GalNAc (2 mM) or the enzyme α-mannosidase (0.05 U/ml) from day −2 to 8. These reagents have been previously shown to reduce the complexity of cell surface O-and N-glycans, respectively. 41−43 However, neither treatment affected TUJ1 expression in the manner that we observed with Ac 4 -5SGlcNAc (Supporting Information Figure 5A ). This observation supports the notion that Ac 4 -5SGlcNAc's effect on neuronal differentiation kinetics is due to inhibition of O-GlcNAcylation rather than altered cell surface glycosylation. As a control experiment, differentiated hESCs treated with α-mannosidase were fixed on day 8 and probed against the lectins Arachis hypogaea agglutinin (PNA) and Canavalia ensiformis agglutinin (ConA) to test the efficacy of α-mannosidase treatment on cells (Supporting Information Figure 5B ). Treatment of cells with α-mannosidase caused a reduction in mannose residues on the cell surface as shown by immunofluorescence imaging with a fluorescent ConA lectin. In contrast, the fluorescent signal of the PNA lectin did not decrease in α-mannosidase-treated cells, as compared to DMSO-treated cells. Overall, our results indicate that further characterization of Ac 4 -5SGlcNAc needs to be performed to better understand the metabolic and phenotypic effects of treating cells with this OGT inhibitor.
OGA Inhibition Does Not Prevent Neural Induction of hESCs. Maintaining high levels of O-GlcNAc in cells has been shown to inhibit neural differentiation of embryonic stem cells.
13,26 Therefore, we examined whether elevating total OGlcNAcylation levels in differentiating hESCs by treatment with the OGA inhibitor Thiamet-G (TMG) prevented cells from differentiating into NPCs. 44 We induced cells from day −2 to 11 in the presence of 100 nM TMG and compared these to cells treated with either 50 μM Ac 4 -5SGlcNAc or DMSO. Treatment of cells with TMG during neural induction caused an increase in total O-GlcNAcylation ( Figure 4A ). Similarly, we observed an increase in OGA expression, whereas OGT expression decreased. As shown by Maury et al., OCT4 levels did not change due to TMG treatment ( Figure 4B ). 26 However, contrary to the study by Maury et al., we did not observe a significant change in PAX6 expression upon treatment with TMG (although significantly higher concentrations were used in their study). As well, we did not observe a difference in the expression of TUJ1 between TMG-treated and DMSO-treated cells nor in the coexpression of MAP2 and TUJ1, as shown by immunofluorescence and flow cytometry, respectively ( Figure 4C,D) . These results suggest that treating differentiating hESCs with 100 nM TMG does not affect the hESC's potential to become NPCs. These findings are consistent with a recent study in which oga disruption in the mouse brain was found to increase neurogenesis. 45 Embryonic stem cells derived from these mice maintained the ability to differentiate in the presence of retinoic acid but failed to express the neuronal marker TUJ1, which further corroborates our findings with Ac 4 -5SGlcNAc. In contrast to what we observed, the differentiated mouse stem cells exhibited altered expression of pluripotency and differentiation markers, such as SOX2 and NESTIN.
OGT Inhibition Upregulates Neuronal Genes. To obtain a more comprehensive view of the role of O-GlcNAc during neural differentiation, we performed RNA-seq analysis every 2 days during neural differentiation of DMSO-and Ac 4 -5SGlcNAc-treated hESCs. Strikingly, except for day 2, the number of genes that were upregulated due to OGT inhibition was always much higher than the number of genes that were downregulated, which suggests that O-GlcNAcylation could function as a repressor of the expression of neural genes ( Figure 5A) . Similarly, the marked difference between the number of upregulated and downregulated genes suggests that the gradual change in the transcriptome, as cells exit pluripotency and enter the neural progenitor stage, is controlled in part by protein O-GlcNAcylation. Day 4 corresponded to the day where the expression of a higher number of genes was affected due to OGT inhibition483 genes total. Interestingly, day 4 coincides with a time point where cells lose expression of OCT4 and start expressing the neural progenitor marker PAX6. This may signify that cells are
Articles exiting the pluripotent state and moving down a path to become NPCs. These changes in transcription are consistent with studies in Drosophila where it has been shown that OGT is encoded by the Polycomb group (PcG) gene, which acts to repress gene expression.
46−48 OGT has also been shown to interact with the Sin3-HDAC complex to promote gene silencing. 49 Consistent with the induction of neural development in OGT-inhibited cells, selected neuronal genes showed an increase in expression ( Figure 5B ). For instance, TUBB3, NEUROD4, RELN, TGFB2, and L1CAM transcripts were all upregulated in Ac 4 -5SGlcNAc-treated cells. Enhanced expression of the TUBB3 gene, which encodes for TUJ1, in Ac 4 -5SGlcNAc-treated cells confirmed our observation of enhanced protein expression as determined by flow cytometry and immunofluorescence microscopy ( Figure 3A−C) . The decrease in expression of FOXG1 and HES5 genes by day 8 suggests that the Ac 4 -5SGlcNAc-treated NPCs are exiting their proliferative state. Gene ontology (GO) term analysis of transcripts on day 4 of differentiation showed that neuron differentiation, forebrain development, and neuron development were significantly enriched categories among upregulated genes in Ac 4 -5SGlcNAc-treated cells compared to DMSOtreated cells ( Figure 5C ). These data demonstrate that a critical time in the differentiation process occurs at least 48 h after induction and that transcriptional changes occur earlier than previously observed at the protein level.
By contrast, transcripts that were downregulated in Ac 4 -5SGlcNAc-treated cells were enriched in categories such as regulation of proteostasis and redox status. Notably, decreased protein O-GlcNAcylation in neuronal cells has been shown to elevate autophagic flux, reduce levels of toxic protein aggregates, and provide protection from neurodegeneration. 50 Modulation of autophagic flux and proteotoxicity has also been observed in Caenorhabditis elegans O-GlcNAc cycling mutants. 51 Thus, we hypothesize that inhibition of OGT in our study could lead to increased mitochondrial activity and autophagic flux, which are known to benefit neuronal health. 52 Continued analysis of key metabolic transitions occurring within the first several days of neural induction may lead to improved understanding of the role that O-GlcNAc plays as a potential regulatory switch from the pluripotent state to the progenitor state, and finally the transition to the postmitotic neuronal fate.
■ CONCLUSION
The results presented in this study further corroborate OGlcNAcylation as a key regulator in the process of embryonic stem cell differentiation to neurons. Our findings that Ac 4 -5SGlcNAc induces expression of neuronal genes as early as day 4 of differentiation and initiates increased axonal branching by day 8 of differentiation suggests a novel mechanism by which in vitro neuronal differentiation can be accelerated. From a practical standpoint, this finding may prove useful for the development of stem-cell-based therapies for neurodegenerative conditions. In the future, it will be important to study whether the effects of OGT inhibition during neural differentiation of hESCs could be reproduced with more specialized neurons, as well as in adult neurogenesis. In addition, these results may contribute new insights into other functions of OGT and O-GlcNAc in the development of the human brain.
■ METHODS Cell Culture. Human embryonic stem cell (hESC) lines H1, H7, and H9 (WA01, WA07, WA09; WiCell) were cultured with hESCqualified basement membrane matrix Matrigel (BD Biosciences). Cells were grown under standard conditions (37°C, 5% CO 2 ) in TeSR2 media (STEMCELL Technologies Inc.). Media were exchanged daily after the first 48 h of cell culture, and cells were passaged every 3 to 5 days using 1 mg mL −1 Dispase (Gibco) and mechanical lifting. Karyotype analysis was routinely performed and indicated that all samples were diploid and had no chromosomal abnormalities.
Neural Induction. hESC lines were differentiated into neural progenitors as reported in ref 27 . Briefly, cells were dissociated using Accutase (STEMCELL Technologies Inc.) and plated on Matrigel (BD Biosciences)-treated dishes at a density of 40 000−50 000 cells/ cm 2 in the presence of MEF-conditioned hESC medium containing 10 ng/mL FGF-2 (R&D Systems) and 10 μM ROCK inhibitor (Y-27632; 
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Articles Tocris). MEF-conditioned hESC medium was obtained by culturing mytomycin-C-treated mouse embryonic fibroblasts (MEF; Millipore PMEF-CF) in DMEM/F12, 20% (v/v) Knockout Serum Replacement, 1 mM GlutaMAX, 100 μM MEM nonessential amino acids, 0.1 mM β-mercaptoethanol (Invitrogen), and 6 ng/mL FGF-2. After 24 h of cell growth, media were harvested and sterile-filtered. The ROCK inhibitor was withdrawn the day after plating, and hESCs were allowed to expand for 3−4 days or until they were 80−90% confluent. Neural differentiation was initiated using KSR medium, which contained Knockout DMEM (Invitrogen), 15% (v/v) Knockout Serum Replacement, 1 mM GlutaMAX, 100 μM MEM nonessential amino acids, and 0.1 mM β-mercaptoethanol. To inhibit SMAD signaling, 100 nM LDN-193189 (Stemgent) or 200 ng/mL Noggin (33-NG-050, R&D Systems) and 10 μM SB431542 (Tocris) were added on days 0−5 of induction. Cells were fed daily, and N2 medium was added in increasing 25% increments every other day starting on day 4 and leading to 100% N2 on day 10. N2 media consisted of 1:1 DMEM/F12 powder (Gibco/Invitrogen) resuspended in distilled 
Articles water, glucose, sodium bicarbonate, putrescine, progesterone, sodium selenite, insulin (Sigma), and apo-transferrin (Kamada Ltd.).
Chemical Inhibitors. Synthesis of Ac 4 -5SGlcNAc was carried out as described previously. 34 Thiamet-G was purchased from Cayman Chemical. hESCs undergoing neural differentiation were treated with a 10 or 50 μM final concentration of OGT inhibitor, starting 2 days before the neural induction began. The inhibitor was added to the media daily throughout the neural induction protocol. To determine the effects of OGA inhibition during neural induction, cells were treated at different times during induction with 100 nM Thiamet-G. DMSO (Sigma) was used as a control for all of the inhibitions.
Cell Surface Glycan Perturbation. hESCs undergoing neural differentiation were treated either with 2 mM of the O-glycosylation inhibitor, benzyl-α-GalNAc (Sigma), or 0.05 U/mL of α-mannosidase (Sigma) from day −2 to 8. Concentrations were determined based on previous literature. 40−42 Western Blot Analysis. Whole cell protein extracts were lysed by probe sonication in buffer consisting of 50 mM Tris-HCl at pH 8.0, 150 mM NaCl, 1% Triton X-100 or Tween, and 2 mM EDTA (including protease and phosphatase inhibitors (Roche) and 1 μM Thiamet-G). Samples were separated by SDS-PAGE (4−12% BioRad), transferred to nitrocellulose membranes, and blocked with 5% milk (LabScientific, inc.) or BSA (Sigma) in PBS with Tween 20 (Sigma). The following primary antibodies were used to detect the indicated proteins: anti-OGT (DM-17, Sigma and sc-32921, Santa Cruz Biotech), anti-OCT4 (MAB4401, Millipore), anti-O-GlcNAc (RL2, Thermo Scientific), anti-OGA (SAB4200267, Sigma), anti-PAX6 (PRB-278P, Covance), antitubulin (T5168, Sigma), anti-GFAT1 (3818, Cell Signaling), anti-GNPNAT1 (SAB2701548, Sigma), anti-PGM3 (sc-100410, Santa Cruz Biotech), anti-UAP1 (GTX103592, GeneTex), anti-NAGK (N6788, Sigma), and anti-GALE (ab155997, abcam). The following horseradish peroxidaselinked secondary antibodies were used for detection at a dilution ratio of 1:5000 goat antirabbit-HRP-conjugated secondary antibody (4010− 05, Southern Biotech) and goat antimouse-HRP-conjugated secondary antibody (1010−05, Southern Biotech).
Immunofluorescence Microscopy. Cells were fixed with 4% (v/ v) paraformaldehyde (Thermo Scientific) for 40 min, rinsed three times with 1× PBS for 5 min, and blocked and permeabilized for at least 1 h with 5% (v/v) FBS plus 0.3% (v/v) Triton X-100 in PBS. Cells were stained with the following primary antibodies: TUJ1 (MAB1637, Millipore), MAP-2 (MAB3418, Millipore), PAX6 (PRB-278P, Covance), and OCT4 (MAB4401, Millipore). Cells were rinsed three times with 1× PBS and were incubated with Alexa Fluor conjugated 488-conjugated goat-antimouse secondary antibody and Alexa Fluor 594-conjugated goat-antirabbit secondary antibody (Invitrogen) for 2 h at room temperature. After, cells were rinsed three times with 1× PBS, and DAPI (Invitrogen) was added for 5 min before analysis using an Olympus IX71 fluorescent microscope. Control cells were stained with mouse and rabbit IgG isotypes (PP54, PP64, Millipore).
Flow Cytometry. Colonies were dissociated with Accutase and rinsed twice with 1× PBS with 0.5% (w/v) BSA. Cells were counted using a hemocytometer, and roughly 1 × 10 6 cells per sample were used for analysis. All cells were fixed with 4% (v/v) paraformaldehyde for 40 min at 4°C, washed twice with PBS, permeabilized using 0.1% (v/v) Triton X-100 in PBS, and blocked using 0.5% (w/v) BSA in PBS. Cells were stained with conjugated antibodies for 20 min in the dark on ice. Primary conjugated antibodies were the following: MAP2-PE (FCMAB318PE, Millipore), TUJ1 Alexa Fluor 488 (560381, BD Pharmingen), MAP2B Alexa Fluor 647 (560382, BD Pharmingen), OCT3/4 Alexa Fluor 647 (560329, BD Pharmingen), and SOX2 Alexa Fluor 488 (561593, BD Pharmingen). Flow cytometry (BD FACs Calibur from BD Biosciences) was performed, and data were analyzed using FlowJo software v9.8.1 (TreeStar Inc.). Total cell population was identified and gated based on characteristic voltage pulse area measurement of forward scatter (FSC: particle size) and side scatter (SSC: granularity/complexity of the particle) of the laser light.
Lectin Analysis. Cells were harvested and fixed in 4% paraformaldehyde at 4°C for 40 min in the dark. Cells were then labeled with five fluorescein isothiocyanate (FITC)-labeled lectins (Vector Laboratories, Inc., Burlingame, CA, USA): Arachis hypogaea agglutinin (PNA), Canavalia ensiformis agglutinin (ConA), Artocarpus integrifolia agglutinin (AIL or Jacalin), and Lens culinaris agglutinin (LCH). All samples were mixed with 50 μg/mL of their designated lectins and incubated for 30 min at room temperature in the dark. The lectin-labeled cell samples were washed three times by centrifuging the samples for 5 min at 300g and then resuspending the resultant pellets in 1× PBS with 5% BSA. For controls, 50 μg/mL of each individual lectin was incubated in 100 mg mL −1 of hapten sugars overnight at 4°C in the dark. After incubation, fixed cell samples were labeled with these sugar-treated lectins and used as controls. The following sugars (monosaccharides) were used as inhibitors: D-galactose (for PNA and Jacalin), N-acetyl-D-galactosamine (for Jacalin), and methyl α-Dmannopyranoside and D-mannose (for ConA and LCA). All samples were analyzed using a BD Accuri C6 flow cytometer, and data were acquired with BD Accuri C6 software (BD Biosciences). Data were analyzed using FlowJo software v9.8.1 (Treestar, Ashland, OR, USA) and gated as described above.
Cell Proliferation. The effect of Ac 4 -5SGlcNAc on cell proliferation was measured using a calorimetric (MTT) kit for cell survival and proliferation (CT02, Millipore) following the manufacturers' instructions.
High Performance Anion Exchange Chromatography (HPAEC). Cells were induced to neural progenitors and harvested as described above. Typically ∼3 × 10 6 cells were harvested per sample. Cells were then lysed with 80% "super-cold" methanol (on dry ice). Lysate was centrifuged at 2000g for 15 min. The supernatant was dried by rotary evaporation for 4−5 h. A metabolite pellet was resuspended in 40 mM sodium phosphate buffer (pH 7.4; 40 μL per million cells) and filtered through an Amicon Ultra centrifugal filter unit (Millipore, 10 000 MWCO). Filtrates were analyzed by HPAEC (ICS-3000 system, Dionex) with CarboPacPA1 (Dionex) with a pulsed amperometry detector (PAD) and UV-detector in-line. 53, 54 Typically, 20 μL of metabolite was injected into the sample loading loop before the sample enters a guard column (Dionex, 4 × 50 mm) and then an analytical column (Dionex, 4 × 250 mm). The eluents used were 1.0 mM NaOH (C) and 1.0 M NaOAc and 1.0 mM NaOH (D). Lowcarbonate NaOH (50% in water) was obtained from Fisher Scientific (SS254−1), and NaOAc was from Sigma (71183). HPAEC was run with a flow rate = 1 mL/min, and the following gradient elution was performed: T 0 min = 95% C, T 5 = 85% C, T 15 = 70% C, T 20 = 60% C, T 45 = 60% C, T 50 = 0% C, T 60 = 0% E2, T 65 = 95%, T 75 = 95%. UDPGlcNAc standards (50 μM, 25 uM, 10 μM, and 2.5 μM) were also analyzed on the same day as cellular samples. UDP-GlcNAc peak areas were calculated by integration and converted to picomoles of UDPGlcNAc by analyzing the peak areas of the UDP-GlcNAc standards and generating a comparable standard curve. Data were normalized to cell number.
RNA-Sequencing and Data Analysis. Total RNA was isolated from cells using the TRIzol Reagent (Invitrogen) and RNeasy Mini kit (Qiagen). RNA quality was assessed using the Agilent 2100 Bioanalyzer. One microgram of each sample was used to isolate mRNA and prepare the library following the protocol of the Illumina TruSeq RNA sample prep kit v2 (RS-122−2001). Prepared libraries were sequenced on an Illumina HiSeq 2500 sequencer Rapid Run mode at the QB3 Vincent J. Coates Genomics Sequencing Laboratory at UC Berkeley. Sequenced reads (27 million) were mapped to the human RefSeq (hg19) using TopHat 55 with default parameters. Differentially expressed genes were identified using Cuffdiff. 56 Biological duplicates for each condition were subjected to the analysis, and the p value cutoff of 0.05 was applied to select significant differences in gene expression for scatter plots and for GO term analysis using DAVID Bioinformatics Resources 6.7.
57
Statistical Analysis. All data are expressed as mean ± SEM. The n represents the number of biological replicates. P values were calculated using the unpaired two-tailed Student's t test. 
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